~~<i id='B23921D71A'><strike id='B23921D71A'><tt id='B23921D71A'><pre id='B23921D71A'></pre></tt></strike></i>~~

Home» explore» knowledge

knowledge

author：knowledge 2025-09-29 01:05:29 Page View：8865

LONDON — GSK said Tuesday it would purchase the asthma-focused drug developer Aiolos Bio for $1 billion upfront, the latest in a string of pharma acquisitions that are bolstering hopes for the industry’s year ahead.

The deal includes up to another $400 million in payments if certain milestones are met.

Aiolos was launched just last year, based in both San Francisco and London. The company, which announced a $245 million Series A round in October, has been readying a Phase 2 trial of its candidate AIO-001 in adult asthma.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： A cyberattack has disrupted hospitals and health care in several states
Next article： Peter Hotez and the public health issue of online harassment

comprehensive

The high cost of giving birth even with insurance

AdobeTheburdenofhighhealthcarecostsandmedicaldebtintheU.S.isnosecret.Medicaldebtaffectsoneinfiveadul

For BCIs, commercial hurdles may be bigger than scientific ones

AdevicecomponentfromParadromicsInc.,oneofthemainbrain-computerinterfaceplayersracingtogettomarket.Co

Peter Hotez and the public health issue of online harassment

AdobeFather’sDayweekendwasanythingbutcalmonTwitter,whicheruptedasvaccineexpertPeterHotezwaschallenge

What the cancer research community can learn from the Covid response

TinaReed,PaulKluetz,JohnOyler,andSolangePetersspeakattheMilkenInstituteFutureofHealthSummit.Screenca